IMV

IMV Inc (formerly known as Immunovaccine Inc; ImmunoVaccine Technologies (IVT)) is a clinical-stage biotechnology company that aims to improve existing vaccines and develop new vaccines by using its proprietary patented technology platform DepoVax to generate depot vaccine formulations of immunogens in liposomes and then in oil carrier which results in significantly enhanced immune responses. The company develops vaccines for cancer and infectious diseases.In May 2018, the company changed its name from "Immunovaccine Inc" to "IMV Inc".Immunovaccine is based in Halifax, Nova Scotia, Canada.In June 2009, Immunovaccine and Rhino Resources signed an agreement under which Rhino would acquire all of Immunovaccine's shares in exchange for Rhino stock. The transaction had been completed by October 2009.In December 2007, Immunovaccine signed a binding memorandum of understanding to acquire Immunotope, the full acquisition was expected to complete by June 2008; howeve